Research Article Details
| Article ID: | A45684 |
| PMID: | 23295629 |
| Source: | Food Chem Toxicol |
| Title: | Protective effects of matrine against progression of high-fructose diet-induced steatohepatitis by enhancing antioxidant and anti-inflammatory defences involving Nrf2 translocation. |
| Abstract: | The present study was aimed to investigate the hepatoprotective effects of matrine against nonalcoholic steatohepatitis induced by a high-fructose diet. After being fed a high-fructose diet (HFD) for 4weeks, male Wistar rats were orally administered matrine in three different doses (40, 80, or 160mg/kg) once daily. Serum and liver samples were collected after treatment with matrine for 4weeks. Lipid droplets within hepatocytes, infiltration of inflammatory cells, and necrotic foci in the liver were morphologically alleviated by matrine in a dose-dependent manner compared with the HFD group. ALT and AST in the blood and the triglyceride content in the liver also decreased. The increased malondialdehyde and depleted glutathione by HFD were ameliorated in a dose-related manner with matrine. Matrine promoted Nrf2 translocation to the nucleus with subsequently up-regulated antioxidative enzyme protein expression, and it enhanced antioxidant activities compared with the HFD group (p<0.05). The increased activity of nuclear factor-kappa B in the liver and the tumour necrosis factor-alpha levels in plasma induced by HFD were inhibited by matrine as well (p<0.05). In this study, we also found that matrine ameliorated HFD-induced hyperglycaemia and insulin resistance. Taken together, our findings demonstrate that matrine is effective in preventing conversion of high-fructose diet-induced hepatic steatosis into nonalcoholic steatohepatitis in rats. |
| DOI: | 10.1016/j.fct.2012.12.043 |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D142 | Fructose | Chemical drug | DB04173 | -- | Intravenous nutrition drug | Under clinical trials | Details |
| D591 | Matrine | Miscellany | -- | -- | Anti-oxidative stress | Under investigation | Details |
| D182 | Insulin | Biological drug | DB00030 | INSR agonist; CPE modulator&product of | -- | Under clinical trials | Details |
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D316 | S-adenosyl-L-methionine | Chemical drug | DB00118 | GNMT cofactor | Antiviral | Under clinical trials | Details |
| D158 | Glutathione | Chemical drug | DB00143 | MGST3; HPGDS; GSTM2; GSTM5; GPX7 cofactor; MGST2; GSS; GSTM1; GSTK1; GSTM3; GSTM4; GPX1 cofactor; GPX2 cofactor; GPX3 cofactor | -- | Under clinical trials | Details |